Global Advanced Drug Delivery System Market Strategic Research Report

Scope of the Report

The global Advanced Drug Delivery System market size is predicted to grow from US$ 26,230 million in 2025 to US$ 48,760 million in 2032; it is expected to grow at a CAGR of 9.4% from 2026 to 2032.

Advanced drug delivery systems (ADMS) refer to a new class of drug delivery technologies that utilize materials science, nanotechnology, bioengineering, microelectronics, and intelligent control to deliver drugs to specific sites or targets in the body in a more precise, efficient, controllable, and patient-friendly manner. Compared to traditional oral tablets or conventional injections, ADMS can achieve sustained release, controlled release, targeted release, cross-biological barrier delivery, and intelligent responsive release, thereby improving drug bioavailability, reducing toxic side effects, prolonging the duration of drug efficacy, and improving patient compliance. This field encompasses various technological routes, including lipid nanoparticles, microspheres, liposomes, implantable drug delivery systems, transdermal patches, inhalation delivery, long-acting injections, microneedles, cell and gene therapy vectors, and antibody-drug conjugate (ADC) delivery platforms. Currently, it is widely used in oncology, diabetes, autoimmune diseases, neurological diseases, and mRNA vaccines.

The future prospects of the advanced drug delivery system industry are very broad, driven by the increasing number of patients with chronic diseases globally, the rapid development of biologics and nucleic acid drugs, the growing demand for precision medicine, and the increasing trend of patients receiving home-based treatment. Especially in emerging therapeutic areas such as mRNA vaccines, siRNA therapy, cell and gene therapy, and targeted cancer drugs, traditional drug delivery methods are no longer sufficient to meet the demands for drug stability and precise delivery. Therefore, Adaptive Drug Delivery Systems (ADDS) have become a crucial direction for the pharmaceutical industry's upgrade. The future industry will develop towards "intelligentization + personalization + long-acting + minimally invasive," with wearable drug delivery devices, AI-controlled release systems, biodegradable implantable devices, and intelligent nanocarriers that respond to changes in body pH/temperature becoming key areas of focus. Simultaneously, with the expiration of numerous blockbuster drug patents, complex formulations and high-barrier delivery systems will become crucial means for pharmaceutical companies to establish a competitive advantage. Consequently, major global pharmaceutical companies, biotechnology companies, and medical device companies are continuously increasing their mergers and acquisitions and R&D investment in this field.

This report presents a comprehensive overview of the global Advanced Drug Delivery System market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• Microsphere Drug Delivery System
• Liposome Drug Delivery System
• Transdermal Drug Delivery System

Segment by Route of Administration

• Oral Delivery
• Injection Delivery
• Lung Inhalation Delivery
• Transdermal Delivery
• Oral Mucosal Delivery
• Others

Segment by Release Modes

• Immediate Release
• Delayed Release
• Continuous Release
• Pulse Release

Segment by Application

• Oncology
• Diabetes
• Cardiovascular Diseases
• Central Nervous System Diseases
• Autoimmune Diseases
• Infectious Diseases
• Vaccine Delivery
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Advanced Drug Delivery System market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Oncology, Diabetes, Cardiovascular Diseases evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact